The collaboration enables Aptar to lead the development and promotion of the Kolibri non-propellant liquid inhaler (NPLI) platform. Under the agreement, Aptar intends to provide Pulmotree with full support to accelerate growth. The company serves as the main point of contact for customers and can complement the Kolibri platform with its own services.
NPLIs like Kolibri include nebulizers and soft-mist inhalers developed as an alternative to propellant-based systems. Kolibri utilizes a breath-triggered vibrating mesh aerosolization engine with breath guidance capabilities to enhance targeted lung deposition. It also comes with connectivity features.
“With this alliance, pharmaceutical partners can access an unprecedented portfolio of services from Aptar Pharma as a single source, in the development of combination products to accelerate product development,” said Ulf Krüger, CEO of Pulmotree. “For Pulmotree, this important step enables us to continue to grow sustainably and expand our portfolio.”
The company says the collaboration further strengthens its leadership in respiratory technology. It enables the company to offer a range of drug delivery formats, solutions and services. The company can customize drug formulation development, optimize device design and differentiate with improved patient outcomes.
“Pulmotree has solid experience in the NPLI field and Aptar Pharma is delighted to be able to offer the Kolibri technology in collaboration with such a knowledgeable partner, to be able to provide full support to all drug developers, from formulation development to patient onboarding,” said Howard Burnett, VP, Global Pulmonary, Aptar Pharma.
